Phytochemicals as lead compounds for...
Egbuna, Chukwuebuka.

FindBook      Google Book      Amazon      博客來     
  • Phytochemicals as lead compounds for new drug discovery
  • 紀錄類型: 書目-電子資源 : Monograph/item
    正題名/作者: Phytochemicals as lead compounds for new drug discovery/ Chukwuebuka Egbuna ... [et al.].
    作者: Egbuna, Chukwuebuka.
    出版者: San Diego :Elsevier, : 2019.,
    面頁冊數: 1 online resource (380 p.)
    附註: 4.1.3.9.2 General toxicity studies
    內容註: Front Cover; Phytochemicals as Lead Compounds for New Drug Discovery; Phytochemicals as Lead Compounds for New Drug Discovery; Copyright; Contents; List of contributors; I -- Plants as natural sources of drugs; 1 -- Plant secondary metabolites as lead compounds for the production of potent drugs; 1.1 Medicinal plants and phytochemicals; 1.1.1 Case Study 1: development of new analogues of combretastatins as tubulin inhibitors; 1.1.2 Case Study 2: development of coumarin analogues as antiretroviral agents; 1.1.3 Case Study 3: oseltamivir phosphate as an antiinfluenza drug; 1.2 Conclusion
    內容註: 3.1.3 Reverse pharmacology3.1.4 Computer-aided drug discovery process; 3.1.4.1 Target identification; 3.1.4.1.1 Genomic techniques; 3.1.4.1.2 Forward and reverse genetics; 3.1.4.1.3 Proteomics; 3.1.4.2 Target validation; 3.1.4.3 Lead identification; 3.1.4.4 Lead optimization; 3.1.5 Structural considerations in drug discovery; 3.1.5.1 Affinity profiling; 3.1.5.2 Target specificity; 3.1.5.3 Quantitative structure-activity relationships; 3.1.5.3.1 1D-QSAR; 3.1.5.3.2 2D-QSAR; 3.1.5.3.3 3D-QSAR; 3.1.5.3.4 Multidimensional quantitative structure-activity relationship; 3.1.5.4 Molecular docking
    內容註: 3.1.6 Bioinformatics and genomics3.1.6.1 Bioinformatics-overview; 3.1.6.2 Bioinformatics tools; 3.1.6.3 Writing language for software packages; 3.1.7 Implications of the human genome project on in silico drug discovery; 3.1.8 Current in silico analyses possible; 3.1.9 ADME-Tox; 3.1.10 Future possibilities; References; 4 -- FDA drug candidacy acceptance criteria and steps: problems and way forward; 4.1 Introduction; 4.1.1 Drug approval framework; 4.1.1.1 The clinical trials; 4.1.2 FDA acceptance of foreign clinical studies not conducted under an IND
    內容註: 4.1.2.1 Acceptance of foreign clinical studies4.1.3 Regulatory approaches on botanical drug development (NDAs); 4.1.3.1 Challenges in developing global botanical drugs; 4.1.3.2 Development of novel botanical drugs using traditional medicinal plant sources; 4.1.3.3 Description and documentation of products; 4.1.3.4 Quality control; 4.1.3.4.1 Quality control systems; 4.1.3.4.2 Record and document control; 4.1.3.5 Botanical raw materials; 4.1.3.6 Safety tests on animals; 4.1.3.7 Placebo; 4.1.3.8 Labeling; 4.1.3.9 Nonclinical safety assessment; 4.1.3.9.1 Pharmacokinetic studies
    標題: Drug development. -
    電子資源: https://www.sciencedirect.com/science/book/9780128178904
    ISBN: 0128178914
館藏地:  出版年:  卷號: 
館藏
  • 1 筆 • 頁數 1 •
  • 1 筆 • 頁數 1 •
多媒體
評論
Export
取書館
 
 
變更密碼
登入